Lilly says its experimental drug retatrutide met the primary endpoint and key secondary endpoints in a new study.

Lilly’s momentum isn’t just about its successful clinical results, though. It’s also about the company’s constant iteration ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...

Just 20% of firms with 200 or more workers said they covered GLP-1 drugs for weight loss, according to the Peterson-KFF ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

GLP-1 medications, including Zepbound and Wegovy, help regulate appetite, support weight loss and improve blood sugar. At the same time, many people experience side effects, especially when they ...

GLP-1 medications, such as Ozempic, Zepbound and Wegovy, have emerged as a significant advancement in the treatment of various conditions, including Type 2 diabetes, heart ...

On the heels of striking a deal with the Trump administration to reduce the prices of several of its most popular drugs for U.S. patients, Eli Lilly has unveiled additional savings for cash-paying ...

Zepbound KwikPen is the newly launched, multi-dose delivery option of Eli Lilly's weight-management medication.